155 related articles for article (PubMed ID: 23385818)
1. Regulation of DU145 prostate cancer cell growth by Scm-like with four mbt domains 2.
Lee K; Na W; Maeng JH; Wu H; Ju BG
J Biosci; 2013 Mar; 38(1):105-12. PubMed ID: 23385818
[TBL] [Abstract][Full Text] [Related]
2. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J
Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255
[TBL] [Abstract][Full Text] [Related]
3. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.
Liu Z; Ren G; Shangguan C; Guo L; Dong Z; Li Y; Zhang W; Zhao L; Hou P; Zhang Y; Wang X; Lu J; Huang B
PLoS One; 2012; 7(7):e40943. PubMed ID: 22808286
[TBL] [Abstract][Full Text] [Related]
4. SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells.
Gwak J; Shin JY; Lee K; Hong SK; Oh S; Goh SH; Kim WS; Ju BG
Oncotarget; 2016 Jul; 7(30):48250-48264. PubMed ID: 27340776
[TBL] [Abstract][Full Text] [Related]
5. Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Cai L; Ma X; Huang Y; Zou Y; Chen X
Oncol Rep; 2014 Jun; 31(6):2593-600. PubMed ID: 24737085
[TBL] [Abstract][Full Text] [Related]
6. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.
Shinojima T; Yu Q; Huang SK; Li M; Mizuno R; Liu ET; Hoon DS; Lessard L
Epigenetics; 2012 Nov; 7(11):1279-89. PubMed ID: 23023649
[TBL] [Abstract][Full Text] [Related]
8. Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.
Shankar E; Pandey M; Verma S; Abbas A; Candamo M; Kanwal R; Shukla S; MacLennan GT; Gupta S
Mol Carcinog; 2020 Aug; 59(8):955-966. PubMed ID: 32391971
[TBL] [Abstract][Full Text] [Related]
9. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
[TBL] [Abstract][Full Text] [Related]
10. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
[TBL] [Abstract][Full Text] [Related]
11. Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I; Wischnewski F; Pantel K; Schwarzenbach H
BMC Cancer; 2010 Jun; 10():297. PubMed ID: 20565761
[TBL] [Abstract][Full Text] [Related]
12. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a.
Yap KL; Li S; Muñoz-Cabello AM; Raguz S; Zeng L; Mujtaba S; Gil J; Walsh MJ; Zhou MM
Mol Cell; 2010 Jun; 38(5):662-74. PubMed ID: 20541999
[TBL] [Abstract][Full Text] [Related]
13. Distinct promoters, subjected to epigenetic regulation, drive the expression of two clusterin mRNAs in prostate cancer cells.
Bonacini M; Coletta M; Ramazzina I; Naponelli V; Modernelli A; Davalli P; Bettuzzi S; Rizzi F
Biochim Biophys Acta; 2015 Jan; 1849(1):44-54. PubMed ID: 25464035
[TBL] [Abstract][Full Text] [Related]
14. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
[TBL] [Abstract][Full Text] [Related]
15. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
16. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
Johng D; Torga G; Ewing CM; Jin K; Norris JD; McDonnell DP; Isaacs WB
Prostate; 2019 Mar; 79(4):414-424. PubMed ID: 30560549
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins.
Majumder S; Kutay H; Datta J; Summers D; Jacob ST; Ghoshal K
J Cell Biochem; 2006 Apr; 97(6):1300-16. PubMed ID: 16329111
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and histone modification regulate silencing of OPG during tumor progression.
Lu TY; Kao CF; Lin CT; Huang DY; Chiu CY; Huang YS; Wu HC
J Cell Biochem; 2009 Sep; 108(1):315-25. PubMed ID: 19565568
[TBL] [Abstract][Full Text] [Related]
19. Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation.
Fouse SD; Shen Y; Pellegrini M; Cole S; Meissner A; Van Neste L; Jaenisch R; Fan G
Cell Stem Cell; 2008 Feb; 2(2):160-9. PubMed ID: 18371437
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
